The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Launched by KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how the expression of a protein called CD19 in different types of cells from patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) affects the success of a specialized treatment called CAR T-cell therapy. CAR T-cell therapy involves using a patient's own immune cells, which are modified in a lab to target and attack cancer cells. The trial aims to understand whether the amount of CD19 present in various cell types can help predict how well patients respond to this therapy.

To participate in this trial, patients of all ages who have been diagnosed with B-ALL and have received CD19-targeted CAR T-cell therapy may be eligible. Researchers will look at samples taken from the patients' bone marrow or blood before and after treatment to measure CD19 levels. By understanding the relationship between CD19 expression and treatment outcomes, the hope is to improve future therapies for patients who may not currently have effective treatment options. Participants can expect to provide samples and contribute to research that could help advance treatment for this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients (adults and pediatrics) with confirmed diagnosis with B-ALL and receipt CD19-targeted CAR-T cell therapy and have diagnostic or post -treatment BM or PB samples processed with a standard B-ALL immunophenotyping panel. with the presence of CD45, CD19, CD34, and CD38 in the antibody panel.